Apple Inc. (AAPL)’s Rise Has Financial Engineering Behind It: John Bright

Apple Inc. (NASDAQ:AAPL) stock is on a tremendous upward trajectory, but can it continue to go upwards? Most investors and analysts marvel at how Apple Inc. (NASDAQ:AAPL) continues to grow its earnings, though there are also some who wonder if the company would be able to replicate past success with the devices it launches in the future. John Bright, Senior Research Analyst at Avondale Partners and Crawford Del Prete, Cgeif Research Officer at IDC Research discussed Apple Inc. (NASDAQ:AAPL)’s recent performance and the upcoming devices from the company on Bloomberg, recently.

Apple AAPL iMac Sales Store Good

“We are actually a ‘Market Outperformer’ on the stock right now. We had upgraded the stock, really got quite lucky, really almost at the bottom of the stock price, the truth is the financial engineering is behind this, we have a $110 price target on the stock today. Apple Inc. (NASDAQ:AAPL) is about technology being simplified and candidly its a matter of how they use their product to generate more usage versus Android,” Bright said.

In the midst of the discussion, a recent tweet from the Billionaire hedge fund manager Carl Icahn was also discussed. In his tweet Icahn had said, that he believed Apple Inc. (NASDAQ:AAPL) to be one of his ‘no-brainers’ and anyone who invested in the stock when Icahn mentioned it would have made a return of 53% (including dividends). Del Prete feels that the recent movement in Apple Inc. (NASDAQ:AAPL) ‘s stock should be attributed to the excitement building around the company’s upcoming launches. He also revealed that if the iPhone 5c and the iPhone 5s are taken out, there are 270-280 million units of the iPhones that can be upgraded. Del Prete believes that Apple Inc. (NASDAQ:AAPL)  is not doing anything much in terms of innovation and dubbed all that is going to happen in the coming months as ‘mother of all upgrade cycles’.

Disclosure: None

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!